CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2004-12-17): Lilly adds warning to Strattera label


Lilly adds warning to Strattera label

Last Updated: 2004-12-17 13:49:29 -0400 (Reuters Health)

NEW YORK (Reuters) - Eli Lilly and Co. said Friday it added a warning to the label of its attention deficit/hyperactivity disorder medicine, advising patients with jaundice or a liver injury to stop taking the treatment.

Lilly said the label change on the drug, known as Strattera, discusses two reported cases of severe liver injury out of the more than 2 million patients who have taken the medication since approval.

Both patients have recovered with normal liver function after discontinuing the medication.

The Indianapolis-based company said it is notifying physicians and other health care providers about this label change.

Lilly said it reported the cases of liver injury to the Food and Drug Administration and reviewed all available data on Strattera, which indicated that the benefit-risk profile remains positive.

Strattera was given during clinical trials to 6,000 patients, who experienced no sign of liver injury, Lilly said. However, patients should contact their doctor if they develop pruritus, jaundice, dark urine, upper right-sided abdominal tenderness, or unexplained flu-like symptoms.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.